MDR-TB support, TB genotyping, and drug susceptibility testing solutions for laboratories working with Mycobacterium tuberculosis complex workflows.
Genient Technologies is your trusted partner in the fight against MDR-TB, working tirelessly to improve healthcare outcomes, ensure patient well-being, and contribute to the global mission of eradicating this challenging disease. Together, we can make a difference in the lives of those affected by MDR-TB and shape a healthier future for all.
One of the pressing healthcare challenges we are dedicated to addressing is Multi-Drug-Resistant Tuberculosis (MDR-TB). MDR-TB is a form of tuberculosis (TB) that has developed resistance to at least two of the most potent first-line anti-TB drugs, isoniazid and rifampicin. This resistance complicates treatment and poses a significant global health concern.
MDR-TB arises when TB bacteria become resistant to isoniazid and rifampicin, rendering standard TB treatments ineffective.
Treating MDR-TB involves prolonged courses of second-line drugs, often with more side effects and lower success rates.
MDR-TB is associated with a higher mortality rate due to treatment challenges and limited drug options.
Genient Technologies is at the forefront of tackling MDR-TB through innovative solutions.
We offer diagnostic tools, including drug susceptibility testing (DST) and rapid molecular tests like GeneXpert, to accurately identify MDR-TB cases.
We support researchers in their quest to better understand MDR-TB, develop new treatments, and advance our collective knowledge.
We are committed to global health and work collaboratively to combat MDR-TB's spread and impact on vulnerable populations.
Genient Technologies offers a TB genotyping and drug susceptibility workflow aligned with DeepChek® assays from ABL Diagnostics. The current portfolio focuses on the 13-Plex KB drug susceptibility testing assay.
A Mycobacterium tuberculosis complex drug susceptibility testing assay for sequencing workflows, suited to small, medium, and high-throughput laboratories.
View Details
Supports unprocessed sputum, concentrated sputum sediments, or MTB-positive culture as described in the assay details.
Designed for Mycobacterium tuberculosis drug susceptibility testing by sequencing using a 13-plex workflow.
BacterioChek TB software ordering information is included for analysis and reporting workflow discussions.